We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPTN
326
DELISTED
OptiNose
OPTN
– –
-200
Closed -$3.12K
PRTA icon
327
Prothena Corp
PRTA
$450M
– –
-5,988
Closed -$124K
PULS icon
328
PGIM Ultra Short Bond ETF
PULS
$18.3B
– –
-10,000
Closed -$497K
QQQ icon
329
PUT
Invesco QQQ Trust
QQQ
$484B
– –
-3,000
Closed -$1.44M
QURE icon
330
uniQure
QURE
$3.22B
– –
-1,222,676
Closed -$5.48M
RLMD icon
331
Relmada Therapeutics
RLMD
$527M
– –
-50,601
Closed -$152K
RYTM icon
332
Rhythm Pharmaceuticals
RYTM
$7.96B
– –
-13,000
Closed -$534K
SHV icon
333
iShares 0-1 Year Treasury Bond ETF
SHV
$20.6B
– –
-24,500
Closed -$2.71M
SNY icon
334
Sanofi
SNY
$104B
– –
-9,100
Closed -$442K
SPY icon
335
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$823B
– –
-8,000
Closed -$4.35M
STVN icon
336
Stevanato
STVN
$5.54B
– –
-27,000
Closed -$495K
SVRA icon
337
CALL
Savara
SVRA
$1.19B
– –
-5,000
Closed -$20.1K
SVRA icon
338
PUT
Savara
SVRA
$1.19B
– –
-11,000
Closed -$44.3K
TLT icon
339
iShares 20+ Year Treasury Bond ETF
TLT
$41.7B
– –
-2,000
Closed -$184K
TSVT
340
DELISTED
2seventy bio
TSVT
– –
-1,000
Closed -$3.85K
TYRA icon
341
Tyra Biosciences
TYRA
$1.58B
– –
-300
Closed -$4.8K
ULST icon
342
State Street Ultra Short Term Bond ETF
ULST
$526M
– –
-47,684
Closed -$1.93M
VERA icon
343
Vera Therapeutics
VERA
$2.36B
– –
-1,079
Closed -$39K
VERV
344
DELISTED
Verve Therapeutics
VERV
– –
-44,000
Closed -$215K
VUSB icon
345
Vanguard Ultra-Short Bond ETF
VUSB
$8.92B
– –
-55,206
Closed -$2.73M
VXRT
346
DELISTED
Vaxart
VXRT
– –
-945,568
Closed -$631K
WVE icon
347
Wave Life Sciences
WVE
$1.2B
– –
-76,651
Closed -$382K
XERS icon
348
Xeris Biopharma Holdings
XERS
$1.45B
– –
-1,000
Closed -$2.25K
XLO icon
349
Xilio Therapeutics
XLO
$60.3M
– –
-107
Closed -$1.42K
YEAR icon
350
AB Ultra Short Income ETF
YEAR
$1.51B
– –
-10,000
Closed -$505K
11 12 13
14
15

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.